Study identifier:D5132C00001
ClinicalTrials.gov identifier:N/A
EudraCT identifier:2009-017242-30
CTIS identifier:N/A
A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events with Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients with History of Myocardial Infarction
myocardial infarction
Phase 3
No
Ticagrelor 90 mg, Ticagrelor 60 mg, Ticagrelor Placebo
All
21379
Interventional
50 Years - 130 Years
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention
Verified 01 Dec 2015 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 Oral Treatment | Drug: Ticagrelor 90 mg Oral dose twice a day |
Experimental: 2 Oral Treatment | Drug: Ticagrelor 60 mg Oral dose twice a day |
Placebo Comparator: 3 Oral Treatment | Drug: Ticagrelor Placebo Oral dose twice a day |